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Open access unda b s t r a c t
Neurocognitive deﬁcits are a core feature of schizophrenia. Deﬁcits covering a wide range of functions
have been well documented. However there is still a lack of longitudinal studies regarding the
development of neurocognitive impairment. The current study examined the effect of time in long-
term treated patients with schizophrenia and healthy controls on cognitive functions. A neurocognitive
test-battery was administered to 36 patients and 46 controls on two occasions with approximately
4.5 years interval. Patients performed signiﬁcantly worse on all measures on both occasions. The only
signiﬁcant decline over time was the ability to shift mental set between different rules or categories
(measured by Trail Making Test B). This decline was present in both patients and controls. Improve-
ment on attention (tested by Continuous Performance Test) was found in patients only and improve-
ment on verbal learning (tested by Rey Auditory Verbal Learning Test) was found only in controls.
Education was signiﬁcantly related to outcome in patients and age was related to outcome in controls.
We conclude that neurocognitive function is relatively stable over 4.5 years in patients with long-term
treated schizophrenia, in line with previous scientiﬁc research. The authors discuss the impact of age
and education and limitations of the study.
& 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Schizophrenia is a condition that affects about one percent of
the population during a lifetime worldwide (Palmer et al., 2005;
McGrath et al., 2008). Life expectancy is lower than for the general
population with ﬁve percent of patients committing suicide and
an increased risk for death by natural causes (Brown, 1997;
Andreasen, 2000; Carlborg et al., 2010). Schizophrenia impairs
the ability to think creatively and imaginatively, to have close
social relationships with other human beings, and to use language
to express ideas with clarity. Even though antipsychotic medica-
tion helps the majority of patients to control the hallucinations
and delusions experienced, medical treatment is less effective in
reducing lack of motivation and ﬂattened affect. The majority of
patients never recover enough to return to full-time work or
sustain a long-term relationship or raise a family and are left with
a life-long disability. The disease counts as one of the ten most
debilitating medical illnesses according to the World Health
Organization (Williamsson, 2005).: þ46 8 346563.
er CC BY-NC-ND license.1.1. Speciﬁc cognitive function deﬁcits associated with schizophrenia
Impaired cognitive functioning is generally considered to be a
primary characteristic of schizophrenia, recognized already by
both Kraepelin and Bleuler (Bozikas et al., 2006). Five domains
have been documented to be of signiﬁcance in patients with
schizophrenia (Lawyer et al., 2006).
1.1.1. Working memory
Working memory is commonly deﬁned as the capacity for
‘‘temporary storage and manipulation of the information neces-
sary for such complex cognitive tasks as language comprehension,
learning and reasoning’’ (Baddeley, 1992). It has been shown by
several authors that patients with schizophrenia have impaired
performance on a variety of working memory tasks. These
ﬁndings have also been used to support the hypothesis that the
prefrontal cortex is impaired in schizophrenia spectrum patients
(Gold et al., 1997; Perry et al., 2001).
1.1.2. Executive function
Executive function is a diverse collection of cognitive abilities,
and refers to the ability to solve problems, use abstract concepts and
manage cognitive skills and resources. Executive function also refers
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and adaptively shift effort in doing so (Harvey and Sharma, 2002).
1.1.3. Psychomotor speed
Psychomotor speed refers to the amount of time it takes a
person to process a signal, prepare a response and execute that
response. This is commonly measured by reaction time. Patients
with schizophrenia have slowed performance on various psycho-
motor measures (Morrens et al., 2007).
1.1.4. Verbal memory/verbal learning
Patients with schizophrenia manifest a number of impairments
in memory functions. When read a story or list of words they
remember less than healthy controls (Saykin et al., 1991). If the list
or story is repeated, patients with schizophrenia learn much less
than healthy controls (Davidson et al., 1996). Still, Karilampi et al.
(2007) found that 44% of patients with schizophrenia, schizo-
affective disorder or delusional disorder had normal learning
ability as measured by Rey Auditory Verbal Learning Test (RAVLT).
1.1.5. Attention/vigilance
It is well known that patients with psychosis and schizo-
phrenia often have disturbances in attention/vigilance and that
this is of great importance for their ability to retain or develop
social abilities. Attentional impairments appear to persist after
remission of acute psychotic episodes (Harvey and Sharma, 2002).
1.2. Evolvement of cognitive functions over time
Neurocognitive impairments do not seem to deteriorate sig-
niﬁcantly over time, implying that schizophrenia is not likely a
progressing degenerative process (Censits et al., 1997; Hoff et al.,
2005). Hoff et al. (2005) concluded that most ﬁrst episode
patients have had considerable cognitive decline by the time of
their ﬁrst hospitalization and that most cognitive change takes
place early in this illness but its exact timing still remains
unknown. In an earlier study by the same research group some
neurocognitive improvement was found also in patients, except
for verbal memory scores. No signiﬁcant change in cognitive
functioning was otherwise found between the patients and the
healthy controls (Hoff et al., 1999).
Some studies have investigated patients with schizophrenia
and healthy controls across age groups. Fucetola et al. (2000)
analyzed the effect of aging on executive functions. They dis-
covered that patients with schizophrenia demonstrated similar
age-related declines across most neuropsychological functions,
with an exception of abstraction ability in which there was
signiﬁcant evidence of a more accelerated decline than in healthy
volunteers. The authors concluded that the results indicated
similar age effects on most aspects of cognition in patients with
schizophrenia and healthy adults but supported the hypothesis
that a degenerative process may result in a more accelerated
decline of some executive functions in older age in schizophrenia
(Fucetola et al., 2000). Another study conducted by Bowie et al.
(2008) found evidence for age-associated cognitive decline on the
more complex components of an information processing test but
not in other neuropsychological tests. These results suggest that
age-related changes in cognitive function in schizophrenia may
be a result of both the course of illness and the processing
demands of the cognitive task of interest (Bowie et al., 2008).
A review of 15 scientiﬁc studies of cognitive functions in
schizophrenia with a follow-up period of at least one year found
the majority of functions to be highly or moderately stable and
some even to be improved. These functions included general IQ,
verbal memory, short-term memory and attention. The onlyfunctions found to show signiﬁcant decline were attention span
and to a lesser degree shifting capacity (Rund, 1998). Friedman et al.
reached the same conclusion: no cognitive decline was found in
patients during a follow-up period of six years (Friedman et al.,
2001). The fact that these authors singled out patients with poor
prognosis made the results particularly interesting since the few
studies that have been conducted with elderly patients with
schizophrenia have focused on poor-outcome populations with long
histories of hospitalization, possibly skewing the picture of cognitive
decline over time (Harvey et al., 1999). Further, Gold et al. (1999)
found improvement in performance and full-scale IQ and no change
in verbal IQ or Wisconsin Card Sorting Test (WCST) among skills
during a follow-up period of ﬁve years (Gold et al., 1999).
Taken together, the literature indicates that patients with
schizophrenia generally perform worse than control subjects on
all the cognitive domains described above. Generally, it seem as
the cognitive decline in patients is present at onset of illness and
does not deteriorate signiﬁcantly during the life span. However,
long-term follow up studies are few, especially in a later phase of
the illness.
In a previous investigation we correlated neurocognitive
measures with structural brain measures from magnetic reso-
nance (MR) images of patients with schizophrenia using a
Bayesian regression method (Lawyer et al., 2006). The patients
performed signiﬁcantly worse than the controls in all neuro-
psychological tests except some regarding executive function
(Lawyer et al., 2006). The most prominent morphological obser-
vations were enlarged ventricles, reduced posterior superior
cerebellar vermis gray matter volumes, and increased putamen
gray matter volumes in the patients. Between 2005 and 2008 the
patients and healthy control subjects of that study, as well as
other subjects who had been investigated neuropsychologically
but not had participated in the MR assessment, were asked to
participate in a ﬁve-year follow-up using the same neuropsycho-
logical tests and procedures. Several of the subjects have also
been included in other previous reports analyzing molecular
genetics, diagnostic, personality, brain volumetric, electroence-
phalographic, obstetric complications and pharmacologic varia-
tions in schizophrenia and related psychosis (Jo¨nsson et al.,
2003a,b, c, 2006a,b, 2008, 2009, 2011, in press; Ekholm et al.,
2005; Agartz et al., 2006; Vares et al., 2006, 2010, 2011; Nesva˚g
et al., 2007, 2008, 2009; Kelly et al., 2008; Lawyer et al., 2008,
2009; Saetre et al., 2008, 2010, 2011; Varna¨s et al., 2008; Andreou
et al., 2009; Haukvik et al., 2009, 2010a,b, 2012; Hartberg et al.,
2010; Caprini et al., 2011; Holtze et al., 2011, 2012; Nikulin et al.,
2012; Lindholm Carlstro¨m et al., 2012).
The aim of the present study was to study putative changes of
neuropsychological functions over a ﬁve-year period in the
patients with schizophrenia as compared to healthy controls.
Further, we aimed to explore any other factors that may be linked
to the neuropsychological test results of patients with schizo-
phrenia speciﬁcally, considering age of onset, duration of illness,
number of hospitalizations and education. We hypothesized
that patients and controls would be stable during the ﬁve-year
period in performance with regard to the addressed cognitive
functions sensitive to schizophrenia, i.e. working memory, execu-
tive function, psychomotor speed, verbal memory/learning and
attention.2. Methods
2.1. Ethics
The study was approved by the Ethics committee of the Karolinska Hospital.
All participating subjects gave informed consent.
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The research subjects who participated in our previous studies (Lawyer et al.,
2006; Hartberg et al., 2010) were drawn from a larger, previously described cohort
(Jo¨nsson et al., 2003d, 2006b). They were unrelated Caucasian individuals living in
Stockholm County. All patients were assessed for life-time psychiatric diagnosis
and geographical origin using reviews of hospital case notes, clinical and/or
structured interviews, and parish register data (Ekholm et al., 2005; Vares et al.,
2006). Only patients fulﬁlling a DSM-III-R or DSM-IV diagnosis of schizophrenia
were included. The healthy controls were drawn from a population register or
recruited among hospital staff members who had previously participated in
clinical studies at Karolinska Institutet as previously described (Jo¨nsson et al.,
2006b; Lawyer et al., 2006; Hartberg et al., 2010). All reviews of hospital case
notes, interviews and diagnostic formulations were performed by a psychiatrist or
a psychiatry resident (Jo¨nsson et al., 2003d).
The patients and controls of the present study (Table 1) were recruited from a
project with the aim to investigate patients with schizophrenia or schizophrenia-
like psychosis, relatives of patients with psychosis and control subjects with
regard to several clinical, brain morphological and neuropsychological assess-
ments (Arnborg et al., 2002). In total 275 subjects had been investigated
neuropsychologically and of those 222 were contacted via mail and telephone
by a research nurse and asked to participate.2.3. Cognitive Performance Indicator (CPI) test battery
The Cognitive Performance Indicator (CPI), a brief neuropsychological test
battery was administrated as a follow-up measurement (Lawyer et al., 2006). CPI
is a semi-computerized test battery, constructed to give an overview of critical
cognitive functions in patients with schizophrenia (Lawyer et al., 2006). The tests
are well known, standardized and have been used extensively in neuropsycholo-
gical examinations (Table 2). The usability and sensitivity to cognitive deﬁcits
generally displayed by patients with schizophrenia are the main reasons for
choosing this test battery. In CPI, the administration of subtests and the registra-
tion of data are guided by a computer program, which makes it easy to use in
clinical as well as research settings. CPI comprises Rey Auditory Verbal LearningTable 1
Demographic and clinical variables presented as mean scores with standard deviation
Patients
Men/women (n) 31/5
Age at baseline (years) 41.1 (7.9
Age at follow-up (years) 45.8 (8.0
Time between baseline and follow-up (years) 4.6 (1.0)
Education (years) 12.3 (2.3
GAF at baseline 48.7 (10
GAF at follow-up 49.8 (10
Illness duration at baseline (years) 17.6 (8.5
Illness duration at follow-up (years) 22.2 (8.5
Hospitalizations (n) 9.6 (10.4
Antipsychotic equivalents at baseline (haloperidol units) 3.3 (2.5)
Antipsychotic equivalents at follow-up (haloperidol units) 4.4 (3.9)
Age of onset (years) 23.6 (4.0
GAF, Global assessment of functioning.
n po0.05.
nnn po0.001.
Table 2
Overview of Cognitive Performance Indicator (CPI): functions measured, names of test
Function Test Measu
Verbal learning RAVLT Total n
Distractor Total n
Memory Total n
Attention CPT (150-item version) d0
Motor speed TMT A Secon
Shift TMT B Secon
Working memory LNS Numb
Executive functions WCST (64 card version) Numb
Numb
Numb
NumbTest (RAVLT), a 150-item version of Continuous Performance Test-Identical
pairs (CPT), Trail Making Test (TMT), Letter–Number-Sequencing (LNS), Wechsler
Adult Intelligence Scale-III (WAIS-III) Vocabulary, and the 64 card version
of the Wisconsin Card Sorting Test (WCST) (Heaton et al., 1993; Lezak, 1995;
Wechsler, 1997).
In the present study, ﬁve of the six domains from the CPI test battery were
used to investigate the performance of patients and healthy controls. The
Vocabulary from WAIS-R used in the previous investigation was excluded since
it is regarded as a ‘‘hold test’’ for roughly assessing pre-morbid functional level.
2.4. Data analysis
A 22 repeated analysis of variance (ANOVA) was conducted with the ﬁrst
factor being group (patients or controls) and the second factor being time
(baseline or follow-up) and the dependent variable being the 17 test scores. These
analyses were performed both without and with education (years of schooling) as
a covariate. A paired-samples t-test was calculated for the within group scores of
the 17 tests to see if the eventual signiﬁcant main effect of time was based on one
groups’ signiﬁcant difference and not the others.
For the three demographic variables available for both groups (sex, age and
years of education) an independent samples t-test was conducted for signiﬁcant
differences between groups. All three variables were then correlated to the 17
mean scores for each group at both baseline and follow-up using Pearson’s and
Spearman’s correlations with two-tailed signiﬁcance. Each of the remaining
demographic variables (age of onset, illness duration and number of hospitaliza-
tions) were then correlated with the 17 test scores for patients at baseline and
follow-up to see if any signiﬁcant correlations would appear, using Pearson’s
correlation with two-tailed signiﬁcance. We set the alpha level to 0.05 for all
statistical analysis.3. Results
The attrition rate was 0.39, 0.16, 0.42 and 0.39 among male
cases, female cases, control men and control women, respectively.in brackets.
Controls Range (patients/controls)
28/18
) 42.4 (7.9) 25.7–55.8/24.5–54.6
) 46.4 (7.9) 28.7–59.7/30.1–59.3
n 4.0 (1.1)n 2.8–6.2/2.5–5.6
)n 13.7 (2.8)n 8–19/9–20
.4)nnn 86.7 (6.1)nnn 30–80/70–90
.8)nnn 82.4(10.0)nnn 30–80/55–90
) 1.2–36.4
) 6.1–39.8
) 0–47
0–8.5
0–19.6
) 16.1–32.2
s and type of measures.
re Reference
umber of correctly reproduced words Lezak (1995)
umber of words reproduced from list B
umber of words reproduced after 20 min
Lezak (1995)
ds Lezak (1995)
ds Lezak (1995)
er of correctly reproduced sequences Wechsler (1997)
er of categories completed Heaton et al. (1993)
er of perseverations
er of total errors
ers of perservative errors
Table 4
Comparison between neuropsychological test results in patients with schizo-
phrenia and control subjects at base-line and at follow-up after ﬁve years
(paired samples t-test). t-Values and signiﬁcance for change over time are shown.
Test Patients Controls
t t
RAVLT 1 0.60 3.78nnn
RAVLT 2 0.85 3.76nnn
RAVLT 3 0.12 1.08
RAVLT 4 1.01 0.34
RAVLT 5 1.30 0.51
RAVLT Total 0.21 2.60n
RAVLT B 0.98 0.22
RAVLT 6 0.44 0.43
RAVLT 7 1.24 1.06
CPT 2.20n 1.60
TMTA 1.37 1.68
TMTB 2.50n 2.91nn
LNS 0.79 0.29
WCST-TC 0.70 0.65
WCST-TE 0.66 0.75
WCST-PE 1.83 0.30
WCST-PR 1.71 0.29
n po0.05.
nn po0.01.
nnn po0.001.
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were: rejected participation (n¼39), no contact (n¼27), dead
(n¼3), moved out of the area (n¼5). Reasons for drop-out among
the 66 controls were: no available time (n¼23), rejected partici-
pation (n¼23), no contact (n¼16), moved out of the area (n¼4).
There was a signiﬁcantly higher drop-out rate among women
with schizophrenia than male cases, control women, and control
men (po0.02). Participating patients and controls tended to be
younger than patient drop-outs and control drop-outs (p¼0.07
and p¼0.03), respectively. There were no signiﬁcant different
scores of Global Assessment of Functioning (GAF) (American
Psychiatric Association, 2000) or the WAIS vocabulary test either
among participating or non-participating patients or participating
or control drop-outs (all p40.3). However, patients who partici-
pated in the follow-up tended to perform better in the subtests
RAVLT 1 (p¼0.05), RAVLT 2 (p¼0.09), RAVLT Total (p¼0.08),
RAVLT B (p¼0.08), CPT (p¼0.08), TMTA (p¼0.03), TMTB (p¼0.09)
and LNS (p¼0.05) than drop-out patients. Controls who partici-
pated tended to perform better in the subtests RAVLT B (p¼0.02)
and TMTB (p¼0.08) than control drop-outs. Among the patients
there were no signiﬁcant differences with regard to age at onset
of illness, number of hospitalizations, or medication as mirrored
by antipsychotic equivalents (Woods, 2003) between participants
and drop-outs. All patients who participated in the study had
sometime been prescribed antipsychotics, but three and six did
not take antipsychotics at base-line or at follow-up, respectively.
There was a signiﬁcant difference between groups on all test
scores at baseline (Table 3; 0.000opo0.05). Likewise, there was
a signiﬁcant difference between groups on all test scores at
follow-up (Table 3; 0.000opo0.05).
Results of the ANOVA showed that for RAVLT 1 there was a
signiﬁcant main effect of time (p¼0.003) as well as a signiﬁcant
main effect of group (p¼0.0001). There was also a signiﬁcant
interaction time/group effect where the controls performed
better than patients at both times but more so during the second
testing (p¼0.028). On RAVLT 2 there was also a signiﬁcant main
effect of time (p¼0.002). On CPT there was a signiﬁcant mainTable 3
Comparison between neuropsychological test results in patients with schizophrenia and
scores (standard deviation in brackets) and F-values for main effect of group, time, and i
covariate.
Test Patients Patients Controls Controls
Baseline Follow-up Baseline Follow-up
RAVLT 1 5.7 (1.5) 5.9 (1.7) 7.0 (1.4) 8.1 (1.9)
RAVLT 2 8.1 (2.5) 8.4 (2.3) 10.0 (1.9) 11.1 (1.9)
RAVLT 3 9.4 (2.6) 9.3 (3.1) 11.9 (1.7) 12.3 (1.9)
RAVLT 4 10.4 (2.6) 10.7 (3.0) 12.9 (1.7) 12.9 (1.8)
RAVLT 5 11.0 (2.8) 10.6 (3.0) 13.8 (1.2) 13.7 (1.3)
RAVLT Total 44.6 (10.8) 44.9 (11.7) 55.7 (6.5) 58.2 (7.6)
RAVLT B 5.2 (1.5) 4.9 (2.1) 7.0 (1.5) 6.9 (1.9)
RAVLT 6 8.8 (3.2) 9.0 (3.0) 12.0 (2.3) 12.2 (2.5)
RAVLT 7 9.2 (3.5) 8.7 (3.2) 12.1 (2.3) 12.5 (2.3)
CPT 0.8 (0.7) 1.1 (0.9) 1.4 (0.8) 1.5 (1.0)
TMTA 32.0 (12.1) 37.2 (25.7) 23.5 (8.0) 25.4 (6.8)
TMTB 94.5 (57.5) 109.2 (70.9) 55.1 (19.8) 62.4 (25.7)
LNS 9.4 (2.6) 9.1 (3.0) 11.5 (2.6) 11.6 (3.0)
WCST-TC 2.7 (1.7) 2.6 (1.9) 3.6 (1.6) 3.7 (1.4)
WCST-TE 22.3 (12.2) 21.3 (12.5) 15.2 (9.4) 14.1 (9.3)
WCST-PE 11.5 (7.3) 9.9 (6.6) 7.3 (4.5) 7.1 (5.1)
WCST-PR 12.8 (8.5) 10.9 (7.8) 7.8 (5.3) 7.6 (5.9)
a F-values without covariate.
b F-values when education was entered as a covariate.
n po0.05.
nn po0.01.
nnn po0.001.effect of time (p¼0.008) and the same result was found for TMT B
(p¼0.0001).
We also performed the calculations above taking the effect of
education into account (Table 3). The results remained essentially
similar, but the effect of time in the analyses concerning RAVLT 1,
RAVLT 2, CPT and TMTB was no longer signiﬁcant, and an effect
with regard to time on TMTA became signiﬁcant (p¼0.03).
The controls had signiﬁcantly increased their scores on the
ﬁrst two trials of RAVLT (p¼0.0001) whereas the patients had not
(Table 4). The controls also showed a signiﬁcant increase in the
total score of RAVLT (p¼0.013) as opposed to the patients. Fig. 1control subjects at base-line and at follow-up after ﬁve years (ANOVA). Mean raw
nteraction group/time with or without entering education (years of schooling) as a
Fa Fa Fa Fb Fb Fb
Group Time Group/time Group Time Group/time
33.6nnn 9.4nn 5.0n 25.8nnn 0.4 4.7n
29.8nnn 10.1nn 3.8 23.9nnn 0.1 3.3
38.0nnn 0.3 0.5 27.6nnn 3.0 0.1
27.4nnn 1.1 0.4 19.5nnn 2.4 1.3
45.0nnn 2.1 0.8 34.0nnn 0.2 0.7
42.7nnn 3.1 2.0 32.3nnn 0.7 1.1
34.2nnn 0.7 0.3 25.8nnn 2.6 0.0
35.6nnn 0.4 0.0 26.1nnn 0.6 0.1
33.4nnn 0.1 2.7 25.2nnn 0.2 2.9
8.1nn 7.4nn 0.4 6.1n 0.1 0.4
14.6nnn 3.9 0.9 9.8nn 4.9n 0.1
19.3nnn 13.8nnn 1.6 12.6nn 0.0 1.9
17.6nnn 0.1 0.6 10.6nn 0.1 0.4
9.2nn 0.0 0.9 4.2n 0.5 0.6
10.7nn 1.0 0.0 5.0n 1.9 0.1
8.9nn 2.4 1.3 4.1n 1.8 2.5
8.9nn 2.2 1.2 4.2n 1.6 2.3
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controls at baseline and follow-up, respectively.
The patients showed a signiﬁcant increase on the CPT
(p¼0.035). Both patients and controls show a signiﬁcant decrease
in performance on the TMT B over time (patients p¼0.017, and
controls p¼0.006) (Table 4).
The patients performed signiﬁcantly below the controls at
both baseline and follow-up (Fig. 2). The patients’ standard
deviation scores ranged from at best 0.57 (WCST-TC) to at
worst 2.29 (RAVLT 5) at baseline, and from at best 0.46 (CPT)0
2
4
6
8
10
12
14
16
RAVLT1 RAVLT2 RAVLT3 RAVLT4 RAVLT5 RAVLT6 RAVLT7
P-baseline
P-followup
C-baseline
C-followup
Fig. 1. Overview of the learning curves of patients (P) and controls (C) at baseline
and follow-up, respectively. RAVLT 1–5 is the rate of learning in trials from 1 to 5.
RAVLT 6 represents the number of words remembered immediately after the list
of distract words (RAVLT B). RAVLT 7 represents the total number of reproduced
words after 20 min.
Fig. 2. Results of neuropsychological test-scores in patients with schizophrenia, when
z-value¼0 on each test at baseline and follow-up.to at worst 2.34 (RAVLT 5) at follow-up, when compared to
controls.
Signiﬁcant correlations were found for a range of tests and
education for patients but less so for controls (Table 5). For
controls test results correlated more with age than for patients
with the exception of WCST. Illness duration correlated only with
aspects of WCST.
No signiﬁcant correlations were found for the variables ‘‘Age of
onset’’ or ‘‘Number of hospitalizations’’ either at baseline or
follow-up for patients (Table 5). With the exception of LNS no
correlations were found for ‘‘Education at baseline’’ for controls
(Table 5).4. Discussion
The main ﬁnding of this study shows that cognitive perfor-
mance over time in patients with schizophrenia does not dete-
riorate compared to a control group. However, some differences
were found which will be discussed as follows.
4.1. Rey Auditory Verbal Learning Test (RAVLT)
The controls showed a signiﬁcant increase in RAVLT trial 1,
2 and Total scores whereas the patients did not. On RAVLT 1 there
was a signiﬁcant interaction effect of time/group which indicates
that controls performed better than patients at both times and
signiﬁcantly more so at follow-up. Rather than reﬂecting a real
change in verbal memory this might imply that controls had a
better advantage of having taken the test at baseline than
patients. Some research shows that healthy controls have a small
but statistically signiﬁcant practise effect in longitudinal studies
over a period ranging from six months to one year (Mitrushina
et al., 2005). The patients did not perform signiﬁcantly worse on
any RAVLT score between the two test occasions indicatingcompared to control subjects. Normalized mean values (z-values), with controls’
Table 5
Signiﬁcant correlations between neuropsychological test-scores and years of education, age or illness duration in patients with schizophrenia (Pat) and control subjects
(Con) at baseline or ﬁve years follow-up. Analyses were also performed for patients with regard to age at onset of illness and number of hospitalizations without signiﬁcant
results.
Test Education Age Illness duration
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Pat Con Pat Con Pat Con Pat Con Pat Pat
RAVLT 1 0.34n 0.39n
RAVLT 2 0.39n
RAVLT 3 0.39n 0.38n
RAVLT 4 0.46nn
RAVLT 5 0.43nn 0.38n
RAVLT Total 0.34n 0.42n 0.32n
RAVLT B 0.41n
RAVLT 6
RAVLT 7
CPT 0.35n 0.43nn 0.51nn 0.45nn
TMTA 0.36n 0.32n
TMTB 0.52nn 0.39n 0.40nn
LNS 0.39n 0.30n 0.62nn
WCST-TC 0.52nn 0.56nn 0.40n
WCST-TE 0.47nn 0.57nn 0.30n 0.38n 0.42n 0.37n
WCST-PE 0.34n 0.43nn 0.36n 0.42n 0.30n 0.45nn 0.33n 0.40n
WCST-PR 0.40nn 0.36n 0.41n 0.31n 0.45nn 0.42n
n po0.05.
nn po0.01.
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earlier research (Hoff et al., 2005).
For the same scores of RAVLT 1, 2 and Total there was a
signiﬁcant correlation with age for the control group but not for
the patients. Previous studies have consistently demonstrated an
effect of age on recall tested by RAVLT in healthy controls
(Mitrushina et al., 2005) and the current ﬁndings for healthy
controls are as expected. The same correlation is not found for the
patient group possibly implying that the illness effect may
dominate over the normal effects of ageing.
For the control group, we found a signiﬁcant correlation between
education at follow-up and RAVLT 3 only. For the patients however,
signiﬁcant correlations between education at baseline and RAVLT
5 and Total were found. In addition, there was a signiﬁcant
correlation between education at follow-up and RAVLT 1, 3, 4, 5,
Total and list B. The results suggest that education is of greater
importance in maintaining neuropsychological function in patients
with schizophrenia than in the healthy population.
4.2. Continuous Performance Test (CPT)
Patients signiﬁcantly improved their performance on CPT at
follow-up whereas the controls did not. This is in contrast to a
previous study, which reported neither signiﬁcant improvement
nor decline over time in patients or controls on CPT (Censits et al.,
1997). However, a more recent report concluded that most
patients’ attention is stable over time and if there is a change, it
tends to be positive rather than negative, which renders our
ﬁndings reasonable (Liu et al., 2006).
Older age has been associated with worse performance on CPT
(Chen et al., 1998; Birkett et al., 2007). Our results replicate this
association in the healthy controls but not among patients,
suggesting that the effect of schizophrenia obscure the normal
effect of ageing on functions measured by CPT. Likewise, educa-
tion has been linked to performance on CPT with more years of
education yielding better performance (Chen et al., 1998). We
found this to be the case for the patient group but not for the
controls whose CPT performance results did not show anycorrelation with education. This is in accordance with the results
from RAVLT in this study, suggesting that education enhances test
performance among patients.
4.3. Trail Making Test (TMT)
Both controls and patients showed signiﬁcant decline on TMT
B over time. The association between older age and poorer TMT
scores has been found among both controls and patients but
appears to be of smaller magnitude in cases with brain injury
(Mitrushina et al., 2005). In our data the signiﬁcant decline in
scores is larger in controls than in patients, which supports the
above mentioned notion.
Earlier research has found a relationship between TMT and
education, where higher level of education is linked to better test
performance in normal individuals (Mitrushina et al., 2005). The
present study failed to replicate this result. However, this rela-
tionship was found in the patient group where patients with more
extended education outperformed those with fewer years of
education. As was the case of the correlations between education
and RAVLT, this might propose that education is of more impor-
tance for the patient group than the control group, perhaps as a
mitigating or protective factor against cognitive decline.
4.4. Letter–Number-Sequencing (LNS)
There was no signiﬁcant decline in LNS scores for either group.
This indicates that no improvement or decline in working mem-
ory occurred within either group. Performance on LNS has been
reported to be highly dependent on both age and education
(Mitrushina et al., 2005) so a relationship should be expected.
For the patients a signiﬁcant correlation was found with educa-
tion but not for age, and for the controls a signiﬁcant correlation
with education was found at baseline but not at follow-up. For
neither groups there were any correlations with age. This is
interesting since our sample is relatively well distributed over
both age and education in both groups. It might be that our
sample of controls is too small to generally detect these
M. Ekerholm et al. / Psychiatry Research 200 (2012) 144–152150relationships, but it might also strengthen our previously
described hypothesis of education being more important for
patients’ later cognitive performance compared to controls.
4.5. Wisconsin Card Sorting Test (WCST)
Neither group showed any signiﬁcant difference in results from
baseline to follow-up on any of the WCST scores. This is in line
with earlier research (Censits et al., 1997; Gold et al., 1999).
However, it should be noted that only a few longitudinal studies
have examined WCST performance in patients with schizophrenia.
In previous studies, there is a well documented negative effect
of age on the WCST but age seems to become a relevant factor
only after approximately 60 years or even later (Mitrushina et al.,
2005). In our study we found that controls’ age and WCST
correlated signiﬁcantly at baseline for perseverative errors and
perseverative responses but this correlation was lost at follow-up.
In our patient group however, age correlated with three of four
WCST scores at baseline and all four at follow-up, indicating that
older patients performed worse than younger at both times. Since
the mean age did not differ signiﬁcantly between cases and
controls this suggests that the ageing process might speed up
cognitive decline in patients but not in controls.
There is a similar effect of education on WCST in the normal
population where its effect is most evident after 15 years of
formal education (Mitrushina et al., 2005). Since both our groups
had mean education levels lower than 15 years it was not
predicted to have a strong effect. What we found is that once
again, in the patient group there were signiﬁcant correlations
between education and WCST but less so among the controls. This
has been found in some other studies regarding education and
WCST (Mitrushina et al., 2005).
There is no clear evidence regarding the effects of illness
duration on WCST, with some studies reporting relationships
and some not (Mitrushina et al., 2005; Vega et al., 2005). We
found a correlation between illness duration and three of four
scores from WCST at follow-up for patients while controlling for
age, indicating that patients perform worse with elapsed illness.
It would be very interesting to follow this cohort over an
extended period of time to investigate the stability of cognitive
functions. Whether this stability is life-long, deteriorates later in life
or perhaps renders patients with schizophrenia more vulnerable to
dementias are questions that remain to be answered.
4.6. Limitations
The present results should be considered against certain
aspects that may have inﬂuenced our ﬁndings. In contrast to most
other follow-up investigations the patients of the present study
were long-term treated already at the base-line assessment. This
means that the results of the present study are not representative
for patients in their early phase of illness. The sample of patients
was also not controlled for the type of medication used and so
there was a variety of different medications represented in the
patient sub-sample. However, there was no correlation (r2o0.02)
between measures of neuroleptic equivalents and attention
among patients, suggesting that this kind of medication did not
severely affected the outcome.
Regarding the relevance of the selection of neuropsychological
tests used, they were selected among well-known reliable and valid
tests tapping the functional domains most often compromised in
schizophrenia, according to the literature. For this reason we
consider the chosen tests to be adequate measures for the study
of neuropsychological functions in patients with schizophrenia.
The attrition rate was high and subsequently the number of
patients and controls included in the study was limited, loweringthe statistical conﬁdence. However, high drop-out rates is com-
mon in demanding follow-up studies performed several years
apart. The current sample of patients had a skewed gender
distribution with signiﬁcantly less women than men compared
to the control group. There have been studies conducted that
show no robust gender differences in neuropsychological perfor-
mance of patients with schizophrenia (Hoff et al., 1998). Still, we
cannot rule out that the relatively larger proportion of women
among controls might have implications for our results, because
previous studies have shown a small but relatively constant
advantage for women on verbal learning tests (Reite et al.,
1993; Mitrushina et al., 2005) and more speciﬁcally on RAVLT
(Messinis et al., 2007).
The educational level of controls and of patients was skewed
with the controls having an average of more than one year of
additional education. However, the results remained overall
similar after taking education into account in the analyses.
Occupation, and whether the patients were working and to what
extent were not controlled for, which are also factors to take into
consideration.
4.7. Summary and conclusions
Overall, our results conﬁrm the ﬁndings from previous studies
of longitudinal change in neuropsychological functioning in
patients with schizophrenia pointing to an essentially stable
course (Censits et al., 1997; DeLisi and Hoff, 2005). The broad
age range of the patients in the present study mirroring particu-
larly a late-phase of this disorder, suggest that an intervention to
prevent cognitive decline – if it is possible – is needed to take
place early in the course of the disorder. The patients show a
cognitive proﬁle that is well below what was found in the control
subjects across a range of tests at both baseline and follow-up, but
no signiﬁcant decline has occurred over time compared to healthy
controls. The patients have signiﬁcantly improved their score on
CPT and the controls have signiﬁcantly improved their scores on
RAVLT trials 1, 2 and Total. Both groups have decreased their
scores on TMT B. We also found signiﬁcant correlations between
neuropsychological measures and education for patients but
much less so among controls. This was an unexpected ﬁnding
and further research regarding this topic might be of interest.
Furthermore, the effect of age was more prominent for the
controls than patients except for the WCST scores for which the
opposite relationship was found.
The present results point to a relationship between education
and cognitive test performance among patients but not among
controls. One must bear in mind that the relationship is not
determined in any one direction, so it might be that patients with
better cognitive functioning from the beginning were able to
acquire longer education and therefore also perform better on CPI,
and not necessarily that education per se is a protective factor,
although there is some research suggesting that conclusion (Vega
et al., 2005). The correlation becomes more interesting when one
ﬁnds that the usual correlation between performance on tests and
education in the healthy population was not found in our sample
to the expected degree. In part this might be due to the relatively
small sample. However, many reports have fewer participants
than ours and so we consider this topic to be of interest to further
investigate.
Generally, performance on cognitive tests becomes worse with
older age. This is the case for the controls but not the patients of
the present study, a result that is to some extent supported by
previous investigators (Vega et al., 2005). The present results give
further support to the notion that schizophrenia as an illness
might obscure the normal decline in age related performance
seen in controls.
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